ADAP240816C5000
- 0.05
- 0.000.00%
Adaptimmune Therapeutics Newsroom
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4
Express News | HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $4 Price Target
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading
Leerink Partners Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
A Quick Look at Today's Ratings for Adaptimmune Therapeutics(ADAP.US), With a Forecast Between $1 to $4
Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)
Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline
Adaptimmune Therapeutics: A Cautious Hold Amid Gradual Launch and Long-Term Growth Strategy
Adaptimmune Therapeutics (ADAP) Gets a Sell From Barclays
Earnings Call Summary | Adaptimmune Therapeutics(ADAP.US) Q2 2024 Earnings Conference
Adaptimmune Therapeutics Plc (ADAP) Q2 2024 Earnings Call Transcript
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading
Express News | Adaptimmune Therapeutics Shares Are Trading Higher. The Company Reported Q2 Financial Results
Earnings Summary: Adaptimmune Therapeutics Beats Q2 Estimates
Adaptimmune Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Adaptimmune Therapeutics Q2 2024 GAAP EPS $0.04 May Not Be Comparable To $(0.08) Estimate, Sales $128.231 May Not Be Comparable To $38.483M Estimate
Express News | Adaptimmune Therapeutics PLC - Qtrly Shr $0.04; Qtrly Revenues $128.2 Mln